Event-Driven Stocks

MAIA Biotechnology, Inc.

MAIANYSE

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21
Revenue—$0$0$0—
Operating income−$24.3M−$17.0M−$20.2M−$16.2M−$7.8M
Net income−$22.4M−$23.3M−$19.8M−$15.8M−$12.6M
Total assets$9.7M$10.2M$7.6M$12.0M$11.3M
Total liabilities$7.3M$6.5M$7.1M$3.5M$2.1M
Equity$2.4M$3.6M$477,511$8.5M$9.2M
EPS (diluted)$-0.70$-1.05$-1.49$-1.75$-2.37
Shares out.29.6M20.0M11.0M11.0M7.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−942.7%
Return on assets
−230.8%
Return on capital (ROCE)
−627.4%
Liabilities / assets
75.5%
Debt / equity
3.08×
Book value / share
$0.08
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-50.68distress
Accruals / assets
−36.6%clean
Piotroski F-Score
1/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
46
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 2 warning● 1 good
  • Altman Z″ in the distress zone
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20262.8M5.0-10.9%
Apr 30, 20263.2M5.0+11.7%
Apr 15, 20262.8M4.1+23.0%
Mar 31, 20262.3M2.9+26.9%
Mar 13, 20261.8M1.0-26.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)